Replies to post #111963 on Biotech Values

[masterlongevity]

thanks, then this is a HUGE advantage for biosimilars.

I worked on that Rituxan clinical development program and it took a lot of phase 3s, a lot of regulatory meetings, and a lot of work and a lot of money to get all those approvals. I would say ~15 ph 3s were needed in the NHL/CLL space over many years to get the broad label that Rituxan has.